Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Third-quarter events to watch for large drug makers
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
UCB’s growth driver squares up against the competition
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.
Big pharma heads towards important readouts
Clinical data are expected soon from Novo Nordisk, Bayer and Sanofi, while Roche and Gilead take aim at ulcerative colitis.
Roche’s test of novel gut target nears
Pivotal ulcerative colitis data on etrolizumab, a dual-action anti-integrin antibody, are due soon, and Roche has Takeda’s Entyvio in its sights.
The crucial data readouts coming soon for small biotechs
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
Will Novo’s big thinking in obesity pay off?
Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.
